

**Form 51-102F3**  
***Material Change Report***

**Item 1      Name and Address of Company**

Mydecine Innovations Group Inc. (the “Company”)  
Suite 810 – 789 West Pender Street  
Vancouver, BC V6C 1H2

**Item 2      Date of Material Change**

August 4, 2022 and August 9, 2022

**Item 3      News Release**

A news release was disseminated on August 12, 2022 through the facilities of Cision and subsequently filed on SEDAR.

**Item 4      Summary of Material Change**

The Company announced the resignation of Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale as directors of the Company effective August 4, 2022, and the resignation of Damon Michaels effective August 9, 2022.

**Item 5      Full Description of Material Change**

**5.1      Full Description of Material Change**

The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency. As a result of the resignations, the Company is currently searching for candidates with a background in drug development to fill two board positions. Josh Bartch, Rob Roscow, and Todd Heinzl have the best interest of the company's stockholders and will continue to serve on the board for the foreseeable future. Mr. Michaels will continue to serve as Chief Operating Officer for the organization.

**5.2      Disclosure for Restructuring Transactions**

Not applicable.

**Item 6      Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7      Omitted Information**

Not applicable.

**Item 8      Executive Officer**

David Joshua Bartch,  
Chief Executive Officer  
604-687-2038  
jbartch@mydecineinc.com

**Item 9      Date of Report**

August 29, 2022